Multiple Myeloma

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.

Binod Dhakal, MD, MS, discusses updated survival data from the CARTITUDE-4 trial of cilta-cel in pretreated, lenalidomide-refractory multiple myeloma.

The European Commission has approved daratumumab plus bortezomib, lenalidomide, and dexamethasone in ASCT-eligible, newly diagnosed multiple myeloma.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Jill Corre, PharmD, PhD, discusses the CASSIOPEIA trial of daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Dr. Saad Usmani discusses the results of the Phase 3 CEPHEUS study, which evaluated the combination of daratumumab with bortezomib/lenalidomide/dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma, highlighting its impact on progression-free survival and minimal residual disease negativity.

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.